Protara Therapeutics, Inc.

NASDAQ•TARA

CEO: Mr. Jesse Shefferman

セクター: Healthcare

業種: Biotechnology

上場日: 2014-10-22

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

連絡先情報

345 Park Avenue South, 3rd Floor, New York, NY, 10010, United States

646-844-0337

www.protaratx.com

時価総額

$239.25M

PER (TTM)

-5.0

19.7

配当利回り

52週高値

$7.82

52週安値

$2.77

52週レンジ

68%

順位68Top 98.2%

1.3

F-Score

改良版 Piotroski 分析

10年ファンダメンタル

弱い • 1.3 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$0.00+0.00%

直近4四半期の推移

EPS

-$0.31-38.00%

直近4四半期の推移

フリーCF

-$12.46M+47.55%

直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Strong TARA-002 Clinical Response BCG-Unresponsive dataset showed 100% CR rate at six months; BCG-Naïve cohort achieved 63% CR rate at six months.

Adequate Liquidity Position Unrestricted cash and marketable debt securities totaled $133.6M as of September 30, 2025; sufficient for twelve months.

Increased Investment Income Other income (expense), net increased $2.3M for nine months, driven by higher returns on invested cash balances.

Common Shares Outstanding Common shares outstanding reached 38.59M as of September 30, 2025, up from 35.04M at year-end 2024.

リスク要因

Widening Net Operating Loss Nine-month net loss widened to $(40.1)M in 2025 from $(31.8)M in 2024, reflecting increased R&D spending.

R&D Expenses Significantly Higher Total R&D expenses rose $7.3M (up 32.9%) for nine months, driven by TARA-002 and IV Choline Chloride startup costs.

Higher Cash Used Operating Cash used in operating activities increased $12.9M to $(39.4)M for nine months due to higher net loss incurred.

Need for Future Capital Company has no near-term revenues and requires substantial additional capital to realize management's drug development plans.

見通し

Advance IV Choline Chloride Plan to dose first patient in registrational THRIVE-3 Phase 3 clinical trial for IV Choline Chloride by end of 2025.

Upcoming TARA-002 Data Expect interim analysis for Cohort B (BCG-Unresponsive) in Q1 2026; update on BCG-Naïve program in Q4 2025.

Focus on Combination Therapies Intend to evaluate TARA-002 combination therapy options for NMIBC and explore other maxillofacial cyst applications.

Unrecognized Stock Compensation Approximately $6.6M in unrecognized stock-based compensation for unvested options expected to be recognized over 2.60 years.

同業比較

売上高 (TTM)

GNFT

$126.71M

+9.8%

CDXS

$52.93M

-17.9%

IVVD

$50.04M

+332.7%

粗利益率 (最新四半期)

GNFT

100.0%

+0.0pp

ASMB

100.0%

+0.0pp

SGMO

100.0%

+0.0pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
SLS	$789.13M	-23.1	-95.2%	1.2%
GNFT	$448.67M	-11.1	-63.7%	64.1%
OBIO	$257.48M	-2.3	-320.1%	15.3%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

N/M

売上高の変動が大きい

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年5月6日

EPS:-

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし